Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line.

Cellular immunology - 1 Jan 2002

Deng Honying, Kowalczyk Dariusz, O InSug, Blaszczyk-Thurin Magdalena, Quan Xiang Zhi, Giles-Davis Wynetta, Ertl Hildegund C J

Abstract excerpt

Different vaccine constructs based on DNA vaccines and viral recombinant vaccines expressing mouse p53 were compared for induction of protective immune responses to challenge with a sarcoma cell line that expresses high levels of mutated p53 protein. Viral recombinant vaccines based on E1-deleted adenovirus or vaccinia virus recombinants expressing p53 with wild-type sequences in the mutational hotspot domain and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-gamma

Share to Methylcholanthrene

Share to Mice, Inbred BALB C

Share to Sarcoma, Experimental

Share to Vaccines, DNA

Share to Viral Vaccines

Source

Identifiers

PMID: 12142033
DOI: 10.1016/s0008-8749(02)00004-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line.PMID 12142033Read ↗

DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis.Semantic proximity Read ↗

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.Semantic proximity Read ↗

DNA-based vaccines for the treatment of cancer--an experimental model.Semantic proximity Read ↗

Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect.Semantic proximity Read ↗

Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.Semantic proximity Read ↗

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.Semantic proximity Read ↗

Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.Semantic proximity Read ↗

TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine.Semantic proximity Read ↗

Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumourSemantic proximity Read ↗

A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.